HDAC2 and colorectal carcinoma: The aim of our study was to investigate the role of HDAC2 in drug resistance and to assess its impact on CRC cell lines with varied TP53 mutation states, (wild-type, null and mutated) in response to the combined treatment with DNA-targeted chemotherapeutics agents and HDACis.